Work

Phase 1b of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with carboplatin (C) and paclitaxel (P) in recurrent platinum-sensitive ovarian cancer (OC).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.2515

Authors: Roisin Eilish O'Cearbhaill, D. Scott McMeekin, Gina Mantia-Smaldone, Camille Gunderson, Paul Sabbatini, Fiore Cattaruzza, Marcus Fischer, Ann M. Kapoun, Lu Xu, Jakob Dupont, Rainer Karl Brachmann, Azeez Farooki, Kathleen N. Moore

Institutions: Memorial Sloan Kettering Cancer Center, University of Oklahoma Health Sciences Center, Fox Chase Cancer Center, OncoMed (United States)

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2695905883

Cites:

Cited by: 13

Related to: 10